NCT02541110

Brief Summary

Second trimester homocysteine \& uterine artery doppler will be assessed\& the cases will be followed up till delivery for development of preeclampsia, IUGR(intra-uterine growth retardation) \& other obstetric complications.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2015

Shorter than P25 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 31, 2015

Completed
1 day until next milestone

Study Start

First participant enrolled

September 1, 2015

Completed
3 days until next milestone

First Posted

Study publicly available on registry

September 4, 2015

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2016

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2016

Completed
Last Updated

September 4, 2015

Status Verified

August 1, 2015

Enrollment Period

4 months

First QC Date

August 31, 2015

Last Update Submit

September 3, 2015

Conditions

PreeclampsiaIUGR

Outcome Measures

Primary Outcomes (1)

  • Number of pregnants who developed preeclampsia, those who developed IUGR alone and those who developed other obstetric complications as preterm labour and placental abruption

    4 months

Eligibility Criteria

Age18 Years - 40 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

Spontaneous pregnancies with no risk factors

You may qualify if:

  • spontaneous pregnancies with no risk factors

You may not qualify if:

  • multiple pregnancies
  • non intact renal function
  • hypertension
  • diabetes
  • folic acid supplements
  • antifolate drugs

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Pre-Eclampsia

Condition Hierarchy (Ancestors)

Hypertension, Pregnancy-InducedPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital Diseases

Study Officials

  • suzy abdelaziz, M.D.

    kasrelaini hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

suzy abdelaziz, M.D.

CONTACT

01003726195suzyabdelaziz92@gmail.com

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
lecturer of Obgyn

Study Record Dates

First Submitted

August 31, 2015

First Posted

September 4, 2015

Study Start

September 1, 2015

Primary Completion

January 1, 2016

Study Completion

February 1, 2016

Last Updated

September 4, 2015

Record last verified: 2015-08